Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Dicerna Pharmaceuticals (DRNA) PT Raised to $20 at SunTrust Robinson Humphrey
September 5, 2018 9:48 AM EDTSunTrust Robinson Humphrey analyst Edward Nash raised the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $20.00 (from $15.00) while maintaining a Buy rating after the company reported PoC data from the ongoing Phase I PHYOX study in primary hyperoxaluria I and... More
